Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of ...
44.0% objective response rate and 10.3-month median progression-free survival observed in non-small cell lung cancer (NSCLC) cohort Phase 3 registration-enabling trial planned in first-line metastatic NSCLC NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- …